Induced-T Cell Like NK Cells for B Cell Malignancies

Summary

Relapsed and refractory B cell malignancies show unfavorable prognosis, especially for adult patients. Now, there is no standard management for these patients. Induced-T cell-like NK cells with chimeric antigen receptor (CAR-ITNK cells) is a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of CAR-ITNK cells infusions in patients with relapsed and refractory B cell malignancies.

Timeline

Start

2021-01-29

Primary completion

2021-12-31

Completion

2022-03-31

Drugs

Indications